Oncolytics Biotech (ONCY) Cash from Financing Activities (2009 - 2025)

Oncolytics Biotech (ONCY) has 17 years of Cash from Financing Activities data on file, last reported at $14.1 million in Q4 2025.

• On a quarterly basis, Cash from Financing Activities rose 490.1% year-over-year to $14.1 million in Q4 2025; TTM through Dec 2025 was $25.1 million, a 420.96% increase from a year earlier, with the FY2025 full-year figure at $14.1 million, up 180.83% from the prior year.
• Cash from Financing Activities for Q4 2025 stood at $14.1 million, up from $3.0 million in the prior quarter.
• Over the last five years, Cash from Financing Activities for ONCY reached as high as $19.9 million in Q1 2021 and fell as low as -$126818.2 in Q3 2024.
• Historically, Cash from Financing Activities has averaged $4.5 million across 5 years, with a median of $2.9 million in 2023.
• Across the five-year window, Cash from Financing Activities plunged 102.42% in 2021 and surged 10505.18% in 2022, its largest moves.
• Year by year, Cash from Financing Activities stood at -$41560.5 in 2021, then surged by 10505.18% to $4.3 million in 2022, then tumbled by 70.41% to $1.3 million in 2023, then surged by 86.8% to $2.4 million in 2024, then soared by 490.1% to $14.1 million in 2025.
• Per Business Quant data, the three most recent Cash from Financing Activities figures were $14.1 million in Q4 2025, $3.0 million in Q3 2025, and $3.9 million in Q2 2025.